Thalidomide neuropathy in childhood

被引：17

作者：

Fleming, FJ

Vytopil, M

Chaitow, J

Jones, HR

Darras, BT

Ryan, MM

机构：

[1] Childrens Hosp Westmead, Inst Neuromusc Res, Westmead, NSW 2145, Australia

[2] Lahey Clin Med Ctr, Dept Neurol, Burlington, MA USA

[3] Childrens Hosp Westmead, Dept Rheumatol, Sydney, NSW, Australia

[4] Childrens Hosp Boston, Dept Neurol, Boston, MA USA

[5] Harvard Univ, Sch Med, Boston, MA USA

[6] Univ Sydney, Fac Med, Sydney, NSW, Australia

来源：

NEUROMUSCULAR DISORDERS | 2005年 / 15卷 / 02期

关键词：

neuropathy; thalidomide; paediatric; coasting;

D O I：

10.1016/j.nmd.2004.10.005

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Thalidomide was withdrawn from world markets in 1961 following recognition of its teratogenic effects. More recently, however, thalidomide treatment has been reintroduced to adult and paediatric practice for a variety of dermatologic, immunologic, rheumatologic and neoplastic disorders. Neuropathy is a significant side effect of thalidomide therapy, which may limit its clinical use. We report four cases of sensorimotor axonal neuropathy in children aged 10-15 years, treated with thalidomide for myxopapillary ependymoma, Crohn's disease and recurrent giant aphthous ulceration. Thalidomide neuropathy is often associated with proximal weakness and may progress even after discontinuation of treatment, in the phenomenon of 'coasting'. Children treated with thalidomide should undergo regular neurophysiologic studies in order to detect presymptomatic or progressive peripheral neuropathy. (C) 2004 Elsevier B.V. All rights reserved.

引用

页码：172 / 176

页数：5

共 22 条

[1]

Incidence and risk factors for thalidomide neuropathy: a prospective study of 135 dermatologic patients [J].